DK1078006T3 - Diagnose og behandling af leverlidelser - Google Patents

Diagnose og behandling af leverlidelser

Info

Publication number
DK1078006T3
DK1078006T3 DK99922996T DK99922996T DK1078006T3 DK 1078006 T3 DK1078006 T3 DK 1078006T3 DK 99922996 T DK99922996 T DK 99922996T DK 99922996 T DK99922996 T DK 99922996T DK 1078006 T3 DK1078006 T3 DK 1078006T3
Authority
DK
Denmark
Prior art keywords
disorders
madcam
disorder
compositions
useful
Prior art date
Application number
DK99922996T
Other languages
English (en)
Inventor
Sherman Fong
Kenneth J Hillan
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK1078006T3 publication Critical patent/DK1078006T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK99922996T 1998-05-13 1999-05-12 Diagnose og behandling af leverlidelser DK1078006T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7840598A 1998-05-13 1998-05-13
PCT/US1999/010520 WO1999058573A1 (en) 1998-05-13 1999-05-12 Diagnosis and treatment of hepatic disorders

Publications (1)

Publication Number Publication Date
DK1078006T3 true DK1078006T3 (da) 2009-06-02

Family

ID=22143829

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99922996T DK1078006T3 (da) 1998-05-13 1999-05-12 Diagnose og behandling af leverlidelser

Country Status (10)

Country Link
EP (1) EP1078006B1 (da)
JP (2) JP4817494B2 (da)
AT (1) ATE424417T1 (da)
AU (1) AU3986699A (da)
CA (1) CA2330000C (da)
DE (1) DE69940503D1 (da)
DK (1) DK1078006T3 (da)
ES (1) ES2321994T3 (da)
IL (2) IL139129A0 (da)
WO (1) WO1999058573A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1308726B1 (en) * 2001-11-05 2006-03-08 Warner-Lambert Company LLC Methods and compositions for screening modulators of integrins
WO2004081049A1 (en) * 2003-03-10 2004-09-23 Auckland Uniservices Limited Monoclonal antibodies that recognise mucosal addressin cell adhesion molecule-1 (madcam-1), soluble madcam-1 and uses thereof
ES2362667T3 (es) 2004-01-09 2011-07-11 Pfizer Inc. ANTICUERPOS FRENTE A MAdCAM.
PE20070374A1 (es) * 2005-07-08 2007-05-12 Pfizer Ltd ANTICUERPOS ANTI-MAdCAM
ES2654820T3 (es) * 2010-10-25 2018-02-15 Biogen Ma Inc. Métodos para determinar diferencias en la actividad de la alfa-4-integrina mediante la correlación de las diferencias en los niveles de sVCAM y/o sMAdCAM
MA41636A (fr) * 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
JP6970975B2 (ja) * 2016-07-20 2021-11-24 国立大学法人京都大学 ＩｇＧ４関連疾患の検査方法
EP3652211A1 (en) 2017-07-14 2020-05-20 Pfizer Inc. Antibodies to madcam
US20200392231A1 (en) * 2017-12-06 2020-12-17 Emory University Methods of Managing Hepatic Steatosis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996024673A1 (en) * 1995-02-10 1996-08-15 Leukosite, Inc. Mucosal vascular addressins and uses thereof
US6037324A (en) * 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor

Also Published As

Publication number Publication date
ATE424417T1 (de) 2009-03-15
ES2321994T3 (es) 2009-06-15
CA2330000A1 (en) 1999-11-18
IL139129A (en) 2006-09-05
JP2002514660A (ja) 2002-05-21
CA2330000C (en) 2015-06-23
EP1078006A1 (en) 2001-02-28
JP2010280659A (ja) 2010-12-16
IL139129A0 (en) 2001-11-25
AU3986699A (en) 1999-11-29
WO1999058573A1 (en) 1999-11-18
DE69940503D1 (de) 2009-04-16
JP4817494B2 (ja) 2011-11-16
EP1078006B1 (en) 2009-03-04

Similar Documents

Publication Publication Date Title
Ridker From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection
BRPI0413326A (pt) métodos para tratar doença cardiovasculares empregando-se uma molécula ctla4 solúvel
Wada Coagulofibrinolytic changes in patients with post-cardiac arrest syndrome
BR0211062A (pt) Combinações para o tratamento de distúrbios inflamatórios
BRPI0712322A2 (pt) compostos e combinações destes para a inibição da produção de beta-amilóide e métodos de uso dos mesmos
DK1078006T3 (da) Diagnose og behandling af leverlidelser
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
BR0008922A (pt) Compostos úteis como agentes antiinflamatórios
EP1140170A4 (en) NOVEL AGENTS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF EYE DISORDERS
EP2801366A3 (en) Improved apo E analogs and methods for their use
André et al. Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosis
DE69833971D1 (de) Verfahren zur behandlung von alzheimerschen krankheit
BRPI0206641B8 (pt) uso de um inibidor da absorção de esteróis
BRPI0606902A2 (pt) composto; método para o tratamento de uma doença ou distúrbio associado a atividade excessiva de bace em um paciente que dele necessite; método para modular a atividade de bace; composição farmacêutica
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
HUP0301727A2 (hu) Eljárás reumatoid artritisz kezelésére oldható mutáns CTLA4 molekula alkalmazásával
EA200000848A1 (ru) Способ селективного снижения числа или активности макрофагов (варианты), способ лечения или профилактики заболевания субъекта (варианты), способ диагностики заболевания у субъекта
TR200002784T2 (tr) Tip 5 ve tip 3 17beta-Hidroksisteroid dehidrojenaz inhibitörleri ve bunların kullanımı için metodlar
McDonald et al. Liver complications following treatment of hematologic malignancy with anti‐CD22‐calicheamicin (Inotuzumab Ozogamicin)
BRPI0413745A (pt) horário mde dosagem para agentes anticancerìgenos erbb2
TR199901904T2 (xx) 3-piridil enantiyomerleri ve bunlar�n analjezik olarak kullan�lmas�.
NO20024646L (no) Kombinasjonsterapier med vaskul¶r-skadende aktivitet
ATE497763T1 (de) Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
WO2008157747A8 (en) Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders
Claus et al. Nootropic drugs in Alzheimer's disease: symptomatic treatment with pramiracetam